Vaxzevria COVID-19 vaccine
E505486
Vaxzevria COVID-19 vaccine is a viral vector coronavirus vaccine created to prevent COVID-19 infection and severe disease in adults.
Statements (46)
| Predicate | Object |
|---|---|
| instanceOf |
COVID-19 vaccine
ⓘ
pharmaceutical product ⓘ |
| belongsToCategory |
SARS-CoV-2 vaccines
ⓘ
adenoviral vector vaccines ⓘ |
| doesNotContain |
live SARS-CoV-2 virus
ⓘ
mRNA ⓘ |
| doseInterval | 4 to 12 weeks ⓘ |
| encodesAntigen | SARS-CoV-2 spike protein ⓘ |
| hasActiveIngredient | ChAdOx1-S NERFINISHED ⓘ |
| hasAdverseEvent |
anaphylaxis
ⓘ
blood clotting disorders ⓘ thrombosis with thrombocytopenia syndrome ⓘ |
| hasAlternativeName |
AZD1222
NERFINISHED
ⓘ
AstraZeneca COVID-19 vaccine NERFINISHED ⓘ ChAdOx1 nCoV-19 NERFINISHED ⓘ Oxford–AstraZeneca COVID-19 vaccine NERFINISHED ⓘ |
| hasClinicalTrialPhase | Phase III completed ⓘ |
| hasCommonSideEffect |
chills
ⓘ
fatigue ⓘ fever ⓘ headache ⓘ injection site pain ⓘ muscle pain ⓘ |
| hasDeveloper |
AstraZeneca
NERFINISHED
ⓘ
University of Oxford NERFINISHED ⓘ |
| hasEfficacy |
high protection against severe COVID-19
ⓘ
reduced risk of symptomatic COVID-19 ⓘ |
| hasManufacturer | AstraZeneca plc NERFINISHED ⓘ |
| hasRegulatoryApproval |
European Medicines Agency
NERFINISHED
ⓘ
World Health Organization Emergency Use Listing NERFINISHED ⓘ |
| hasRegulatoryStatusChange | suspended or restricted in some countries ⓘ |
| hasVaccinePlatform | non-replicating viral vector ⓘ |
| indicatedForAgeGroup |
18 years and older
ⓘ
adults ⓘ |
| isGeneticMaterialType | DNA ⓘ |
| isNonReplicating | true ⓘ |
| prevents |
COVID-19-related death
ⓘ
COVID-19-related hospitalization ⓘ SARS-CoV-2 infection ⓘ severe COVID-19 ⓘ |
| routeOfAdministration | intramuscular injection ⓘ |
| storageTemperature | refrigerated 2–8 °C ⓘ |
| targetsDisease | COVID-19 NERFINISHED ⓘ |
| typicalDoseCount | 2 doses ⓘ |
| usesVector | chimpanzee adenovirus ⓘ |
| wasFirstUsedIn | 2020 ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.